Research Study Needs You
April 21, 2014
The Ohio State University is seeking study participants on Tysabri or Copaxone. If you volunteer to participate in this research study, you will be scheduled to come in to the OSU Medical Center for a Screening/Baseline visit (2 parts, 7hours, total for both parts), 6 month visit (1 part, 1½ hrs), and 12 month visit (2 parts, 7 hours, total for both parts). You will be provided $35.00 reimbursement for each of these three visits. You will also be contacted by phone at months 2, 4, 8 and 10 to follow up on medication compliance and to keep your medications list current. During the study you will have the following procedures: a neurological evaluation, an expanded disability status scale exam, a MRI and neuropsychological evaluation.
The study is recruiting Relapsing-Remitting MS patients (age 18-60y) who are willing and able to participate in MRI using a stronger magnet than conventional MRI. To be able to access the stronger MRI, patients cannot have any metal in their body. They also have to be able to step up 2 steps to the patient table of the stronger MRI and should not be claustrophobic. Patients with Secondary-Progressive MS, Primary-Progressive MS, or patients who are pregnant or planning to become pregnant cannot participate in this study.
For more information, contact call Petra Schmalbrock at 614-571-5978 or email her at Petra.firstname.lastname@example.org.
About Multiple Sclerosis
Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.